Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: the NAN trial

While therapies such as chemotherapy combined with immunotherapy, sacituzumab govitecan, and PARP inhibitors are available for metastatic TNBC, on disease progression after these therapies, the mainstay of therapy is chemotherapy. Apatinib is a small-molecule tyrosine kinase inhibitor that has promi...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Dou-Dou, Tao, Zhong-hua, Wang, Bi-Yun, Wang, Lei-Ping, Cao, Jun, Hu, Xi-Chun, Zhang, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9489776/
https://www.ncbi.nlm.nih.gov/pubmed/36127351
http://dx.doi.org/10.1038/s41523-022-00462-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9489776/
https://www.ncbi.nlm.nih.gov/pubmed/36127351
http://dx.doi.org/10.1038/s41523-022-00462-6

Ejemplares similares